Request Trial
shutterstock_1231106194_pajor_pawel
Pajor Pawel / Shutterstock.com
1 February 2021Rory O'Neill

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Teva faces scrutiny over efforts to curb generic competition
27 August 2026   Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
Regulation & Industry
FDA targets faster generic approvals in drive to slash drug prices
27 August 2026   Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.
Biotech
China-origin biotech assets and the hidden question of IP ownership
27 August 2026   As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler


Editor's picks

The buyers' wishlist: What makes a life sciences deal stack up?
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026

Editor's picks

Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

More features

Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026
Teva faces scrutiny over efforts to curb generic competition
FDA targets faster generic approvals in drive to slash drug prices
China-origin biotech assets and the hidden question of IP ownership
Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice
The buyers' wishlist: What makes a life sciences deal stack up?
UK appoints ex-engineer as new intellectual property Minister
Stris & Maher opens new Dallas office with partner hires